Skip to content

Trial Summary

RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.



ACTRN/NCT /ethics:


Scientific title:

The Role of Androgen Deprivation Therapy In Cardiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)

Sponsor / Cooperative group:

McMaster University

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
Age Range45 Years and older
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2015-10-21
Anticipated End Date2025-12-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Braden Higgs
Recruitment StatusRecruiting